NantKwest Launches Initial Public Offering

NantKwestNantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company, has commenced an initial public offering of 7,000,000 shares of its common stock.

The estimated price range of the common stock is between $20.00 and $23.00 per share. The underwriters of the offering will have a 30-day option to purchase up to an additional 1,050,000 shares of common stock from NantKwest at the initial public offering price, less customary underwriting discounts and commissions.
The company has applied to have its shares of common stock approved for listing on the Nasdaq Global Select Market under the symbol “NK”.
In addition, existing stockholder Celgene Corporation has agreed to purchase $17.0 million of shares of NantKwest common stock in a separate private placement concurrent with the offering at a price per share equal to the initial public offering price.
BofA Merrill Lynch, Citigroup Global Markets Inc., Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and MLV & Co. LLC is acting as co-manager.

NantKwest focuses on harnessing the innate immune system by using the Natural Killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases.



Join the discussion